Charles River Laboratories is undergoing a strategic transformation under the leadership of CEO James Stern, who took the helm in 2022. A longtime insider with over two decades at the company, Stern is bringing a fresh perspective to the drug development services provider.

Stern previously served as president and COO, gaining deep operational knowledge across the organization. His elevation to CEO marked a shift toward more aggressive cost management and portfolio optimization. The company has faced pressure from investors to improve margins amid slowing growth in its core contract research services.

Under Stern's leadership, Charles River has implemented a comprehensive restructuring program. The initiative includes workforce reductions affecting approximately 1,300 employees globally, representing about 6% of the workforce. These measures aim to streamline operations and focus resources on higher-margin segments.

The restructuring efforts reflect Stern's vision of transforming Charles River into a more efficient organization. By emphasizing innovation in early-stage drug development and reducing administrative overhead, the company seeks to deliver better value to clients and shareholders alike. Industry analysts closely watch these changes as the life sciences sector navigates evolving market dynamics.